The molecular concept of atheromatous plaques

Zar Chi Thent, Chiranjib Chakraborty, Pasuk Mahakkanukrauh, Nik Ritza Kosai Nik Mahmood, Reynu Rajan, Srijit Das

Research output: Contribution to journalReview article

Abstract

Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. Objective: The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous plaques. Methods: A thorough literature search of Pubmed, Google and Scopus databases was done. Results: Atherosclerosis is considered to be a leading cause of death throughout the world. Atherosclerosis involves oxidative damage to the cells with production of reactive oxygen species (ROS). Development of atheromatous plaques in the arterial wall is a common feature. Specific inflammatory markers pertaining to the arterial wall in atherosclerosis may be useful for both diagnosis and treatment. These include Nitric oxide (NO), cytokines, macrophage inhibiting factor (MIF), leucocytes and Pselectin. Modern therapeutic paradigms involving endothelial progenitor cells therapy, angiotensin II type-2 (AT2R) and ATP-activated purinergic receptor therapy are notable to mention. Conclusion: Future drugs may be designed aiming three signalling mechanisms of AT2R which are (a) activation of protein phosphatases resulting in protein dephosphorylation (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway by vasodilation and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovascular system.

Original languageEnglish
Pages (from-to)1250-1258
Number of pages9
JournalCurrent Drug Targets
Volume18
Issue number11
DOIs
Publication statusPublished - 2017

Fingerprint

Atherosclerotic Plaques
Purinergic Receptors
Atherosclerosis
Nitric Oxide
Adenosine Triphosphate
Chemical activation
Pharmaceutical Preparations
Cardiovascular system
Molecular biology
Phospholipases A
Macrophages
Phosphoprotein Phosphatases
Cyclic GMP
Endothelial cells
Purinergic P2X7 Receptors
Bradykinin
Biotechnology
Arachidonic Acid
Angiotensin II
Reactive Oxygen Species

Keywords

  • Anatomy
  • Atherosclerosis
  • Cells
  • Inflammatory
  • Microstructure
  • Plaques
  • Therapeutic

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

The molecular concept of atheromatous plaques. / Thent, Zar Chi; Chakraborty, Chiranjib; Mahakkanukrauh, Pasuk; Nik Mahmood, Nik Ritza Kosai; Rajan, Reynu; Das, Srijit.

In: Current Drug Targets, Vol. 18, No. 11, 2017, p. 1250-1258.

Research output: Contribution to journalReview article

Thent, ZC, Chakraborty, C, Mahakkanukrauh, P, Nik Mahmood, NRK, Rajan, R & Das, S 2017, 'The molecular concept of atheromatous plaques', Current Drug Targets, vol. 18, no. 11, pp. 1250-1258. https://doi.org/10.2174/1389450117666160502151600
Thent, Zar Chi ; Chakraborty, Chiranjib ; Mahakkanukrauh, Pasuk ; Nik Mahmood, Nik Ritza Kosai ; Rajan, Reynu ; Das, Srijit. / The molecular concept of atheromatous plaques. In: Current Drug Targets. 2017 ; Vol. 18, No. 11. pp. 1250-1258.
@article{261b967f9c0b43c0bc3ed7dd7bb39c6b,
title = "The molecular concept of atheromatous plaques",
abstract = "Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. Objective: The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous plaques. Methods: A thorough literature search of Pubmed, Google and Scopus databases was done. Results: Atherosclerosis is considered to be a leading cause of death throughout the world. Atherosclerosis involves oxidative damage to the cells with production of reactive oxygen species (ROS). Development of atheromatous plaques in the arterial wall is a common feature. Specific inflammatory markers pertaining to the arterial wall in atherosclerosis may be useful for both diagnosis and treatment. These include Nitric oxide (NO), cytokines, macrophage inhibiting factor (MIF), leucocytes and Pselectin. Modern therapeutic paradigms involving endothelial progenitor cells therapy, angiotensin II type-2 (AT2R) and ATP-activated purinergic receptor therapy are notable to mention. Conclusion: Future drugs may be designed aiming three signalling mechanisms of AT2R which are (a) activation of protein phosphatases resulting in protein dephosphorylation (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway by vasodilation and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovascular system.",
keywords = "Anatomy, Atherosclerosis, Cells, Inflammatory, Microstructure, Plaques, Therapeutic",
author = "Thent, {Zar Chi} and Chiranjib Chakraborty and Pasuk Mahakkanukrauh and {Nik Mahmood}, {Nik Ritza Kosai} and Reynu Rajan and Srijit Das",
year = "2017",
doi = "10.2174/1389450117666160502151600",
language = "English",
volume = "18",
pages = "1250--1258",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - The molecular concept of atheromatous plaques

AU - Thent, Zar Chi

AU - Chakraborty, Chiranjib

AU - Mahakkanukrauh, Pasuk

AU - Nik Mahmood, Nik Ritza Kosai

AU - Rajan, Reynu

AU - Das, Srijit

PY - 2017

Y1 - 2017

N2 - Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. Objective: The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous plaques. Methods: A thorough literature search of Pubmed, Google and Scopus databases was done. Results: Atherosclerosis is considered to be a leading cause of death throughout the world. Atherosclerosis involves oxidative damage to the cells with production of reactive oxygen species (ROS). Development of atheromatous plaques in the arterial wall is a common feature. Specific inflammatory markers pertaining to the arterial wall in atherosclerosis may be useful for both diagnosis and treatment. These include Nitric oxide (NO), cytokines, macrophage inhibiting factor (MIF), leucocytes and Pselectin. Modern therapeutic paradigms involving endothelial progenitor cells therapy, angiotensin II type-2 (AT2R) and ATP-activated purinergic receptor therapy are notable to mention. Conclusion: Future drugs may be designed aiming three signalling mechanisms of AT2R which are (a) activation of protein phosphatases resulting in protein dephosphorylation (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway by vasodilation and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovascular system.

AB - Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. Objective: The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous plaques. Methods: A thorough literature search of Pubmed, Google and Scopus databases was done. Results: Atherosclerosis is considered to be a leading cause of death throughout the world. Atherosclerosis involves oxidative damage to the cells with production of reactive oxygen species (ROS). Development of atheromatous plaques in the arterial wall is a common feature. Specific inflammatory markers pertaining to the arterial wall in atherosclerosis may be useful for both diagnosis and treatment. These include Nitric oxide (NO), cytokines, macrophage inhibiting factor (MIF), leucocytes and Pselectin. Modern therapeutic paradigms involving endothelial progenitor cells therapy, angiotensin II type-2 (AT2R) and ATP-activated purinergic receptor therapy are notable to mention. Conclusion: Future drugs may be designed aiming three signalling mechanisms of AT2R which are (a) activation of protein phosphatases resulting in protein dephosphorylation (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway by vasodilation and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovascular system.

KW - Anatomy

KW - Atherosclerosis

KW - Cells

KW - Inflammatory

KW - Microstructure

KW - Plaques

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85028991757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028991757&partnerID=8YFLogxK

U2 - 10.2174/1389450117666160502151600

DO - 10.2174/1389450117666160502151600

M3 - Review article

C2 - 27138760

AN - SCOPUS:85028991757

VL - 18

SP - 1250

EP - 1258

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 11

ER -